Statins and immune checkpoint inhibitors: a strategy to improve the efficacy of immunotherapy for cancer?
Open Access
- 2 September 2022
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 10 (9) , e005611
Abstract
In the past decade, immune checkpoint inhibitor (ICI) therapy significantly improved the prognosis of patients with cancer. Despite impressive and often unprecedented response rates, a significant portion of the patients fails to benefit from this treatment. Additional strategies to improve ICI efficacy are therefore needed. The widespread clinical use of ICIs has increased our knowledge on the effects of the concomitant use of commonly prescribed drugs on the outcome of ICI treatment. A particular interesting class of drugs in this context are statins. These HMG-CoA reductase inhibitors, which are used to treat hypercholesterolemia and reduce the risk for atherosclerotic cardiovascular disease, are frequently used by patients with (advanced) cancer. This paper addresses the hypothesis that statins improve the efficacy of ICI therapy.Keywords
Funding Information
- Amsterdam Cardiovascular Sciences (N/A)
- Heart Foundation (N/A)
This publication has 10 references indexed in Scilit:
- A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective studyBMC Cancer, 2022
- Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancerJournal for ImmunoTherapy of Cancer, 2021
- High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patientsEuropean Journal of Cancer, 2021
- The effect of concomitant use of statins, NSAIDs, low-dose aspirin, metformin and beta-blockers on outcomes in patients receiving immune checkpoint inhibitors: a systematic review and meta-analysisOncoImmunology, 2021
- Inhibition of PCSK9 potentiates immune checkpoint therapy for cancerNature, 2020
- Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practiceJournal for ImmunoTherapy of Cancer, 2020
- Evolving impact of long-term survival results on metastatic melanoma treatmentJournal for ImmunoTherapy of Cancer, 2020
- Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic PlaqueCirculation, 2020
- Concomitant medications and immune checkpoint inhibitor therapy for cancer: causation or association?Human Vaccines & Immunotherapeutics, 2020
- Cholesterol Induces CD8+ T Cell Exhaustion in the Tumor MicroenvironmentCell Metabolism, 2019